Penumbra, Inc. completed the acquisition of Sixense Enterprises Inc. for approximately $250 million.
October 30, 2021
Share
Penumbra, Inc. (NYSE:PEN) entered into an agreement to acquire Sixense Enterprises Inc. for approximately $170 million on September 17, 2021. Under the terms, Penumbra expected to issue approximately 600,000 shares as consideration. Post completion, all outstanding shares of Sixense capital stock will be cancelled. The acquisition is subject to certain conditions and is expected to close on October 1, 2021.
Penumbra, Inc. (NYSE:PEN) completed the acquisition of Sixense Enterprises Inc. for approximately $250 million on October 1, 2021. Under the terms, Penumbra issued 661,877 shares as consideration. Additionally, on October 1, 2021, Penumbra converted all stock options held by Sixense service providers that would continue as service providers after the merger into fully vested options to purchase an aggregate amount of 447,017 shares of the Company's common stock
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
PENUMBRA, INC. 
